New drug shows promise for controlling rare immune disorder
NCT ID NCT05063110
First seen Jan 05, 2026 · Last updated Jun 18, 2026 · Updated 25 times
Summary
This study tested the drug ITACITINIB in 35 adults with a mild form of a rare immune disease called HLH. The goal was to see if the drug could control the disease by improving symptoms within 15 days. The trial is now complete, and results will show how well the drug works for this condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hôpital Avicenne
Bobigny, Bobigny, 93000, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.